New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2012
10:30 EDTCRM, CLP, CCG, UA, CRUS, PG, CPT, AVB, BAX, TGT, HCCI, PPS, GB, MAROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Target (TGT) upgraded to Buy from Hold at Jefferies...Cirrus Logic (CRUS) upgraded to Outperform from Perform at Oppenheimer...Marriott (MAR) upgraded to Conviction Buy from Buy at Goldman...Baxter (BAX) upgraded to Neutral from Sell at Citigroup...Under Armour (UA) upgraded to Overweight from Equal Weight at Morgan Stanley...Greatbatch (GB) upgraded to Neutral from Underweight at Piper Jaffray...AvalonBay (AVB) upgraded to Outperform from Underperform at Credit Suisse...Campus Crest (CCG) upgraded to Buy from Neutral at Janney Capital...Post Properties (PPS) upgraded to Buy from Neutral at UBS...Camden Property (CPT) upgraded to Buy from Neutral at UBS...Colonial Properties (CLP) upgraded to Buy from Neutral at UBS...Heritage-Crystal Clean (HCCI) upgraded to Buy from Hold at Needham...Procter & Gamble (PG) upgraded to Buy from Neutral at Buckingham...Salesforce.com (CRM) upgraded to Buy from Hold at ThinkEquity.
News For TGT;CRUS;MAR;BAX;UA;GB;AVB;CCG;PPS;CPT;CLP;HCCI;PG;CRM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 1, 2015
07:34 EDTMARW.P. Carey JV purchases the Ritz-Carlton, Fort Lauderdale Property
Subscribe for More Information
07:25 EDTPGConsumer goods makers challenged by surging freight costs, WSJ reports
Subscribe for More Information
June 30, 2015
15:31 EDTPGProcter & Gamble announces change to laundry pacs to improve safety
Subscribe for More Information
12:59 EDTCRMSalesforce management to meet with UBS
Subscribe for More Information
June 28, 2015
16:00 EDTCRMFormer Salesforce CFO Graham Smith to depart June 30
Subscribe for More Information
12:47 EDTCRMTech sector earnings 'melt away' when accounting for stock comp, Barron's says
Subscribe for More Information
June 26, 2015
11:40 EDTUANike hits 52-week high after strong Q4 results, positive analyst commentary
Subscribe for More Information
10:00 EDTTGTOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARM Holdings (ARMH) downgraded to Underperform from Market Perform at Bernstein... Apogee Enterprises (APOG) downgraded to Market Perform from Outperform at Northland... Atlas Resource Partners (ARP) downgraded to Underperform from Neutral at BofA/Merrill... Bank of the Ozarks (OZRK) downgraded to Hold from Buy at Drexel Hamilton... China Cord Blood (CO) downgraded to Neutral from Buy at Roth Capital... Citizens Financial (CFG) downgraded to Neutral from Buy at Guggenheim... Community Health (CYH) downgraded to Market Perform from Outperform at Raymond James... Eagle Bancorp (EGBN) downgraded to Hold from Buy at Sandler O'Neill... Fifth Street Senior (FSFR) downgraded to Neutral from Buy at UBS... FireEye (FEYE) downgraded to Equal Weight from Overweight at Barclays... Insight Enterprises (NSIT) downgraded to Underperform at Raymond James... Micron (MU) downgraded to Neutral from Buy at Mizuho... SYNNEX (SNX) downgraded to Hold from Buy at Needham... Swatch Group (SWGAY) downgraded to Equal Weight from Overweight at Barclays... Target (TGT) downgraded to Market Perform from Outperform at BMO Capital... Zoetis (ZTS) downgraded to Market Perform from Outperform at BMO Capital.
07:40 EDTTGTTarget downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Target to Market Perform citing near-term leadership uncertainty at a time when shares are trading near 52 week and all-time highs. BMO Capital's analyst said it was surprised by the announcement that Kathee Tesija, EPV and Chief Merchandising and Supply Chain Officer will transition into an advisory role but does not view it as a disagreement in strategic direction.
June 25, 2015
10:00 EDTMAROn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:03 EDTTGTTarget: Chief Merchandising and Supply Chain Officer to move to advisory role
Subscribe for More Information
08:47 EDTMARMarriott and Universal Music Group launch global marketing partnership
Subscribe for More Information
08:26 EDTTGTTarget management to meet with Evercore ISI
Field trip to company headquarters to be held in Minneapolis on June 29 hosted by Evercore ISI.
07:06 EDTBAXMerrimack's MM-398 NDA granted priority review by FDA
Merrimack (MACK) and Baxalta Incorporated, a wholly-owned subsidiary of Baxter (BAX) announced that the New Drug Application for MM-398 has been accepted for review by the FDA. Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. In addition, the FDA has classified the NDA as having Priority Review status. The FDA has set a goal of October 24 to take action under the Prescription Drug User Fee Act. The European Medicines Agency has also accepted for review a Marketing Authorization Application for MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. The acceptance of the MAA marks the beginning of the review process in the European Union for MM-398 in this indication.
05:29 EDTMARMarriott initiated with a Hold at Brean Capital
Subscribe for More Information
June 24, 2015
17:18 EDTUAChamps Sports, Under Armour launch premium store-within-store concept
Champs Sports, a member of the Foot Locker (FL) family, is collaborating with Under Armour (UA) to launch The ARMOURY at Champs Sports. This is the first-of-its-kind, premium store-within-a-store and will open later this month at the Champs Sports store in The Mall in Columbia in Columbia, MD.
11:16 EDTUAOptions with increasing implied volatility
Options with increasing implied volatility: WMB AMZN CMG BIIB VMW QLIK ISRG FB UA FFIV
June 23, 2015
18:07 EDTBAXBaxter initiated with a Buy at Goldman
Subscribe for More Information
06:33 EDTPGOnline market for razors growing quickly, WSJ reports
Subscribe for More Information
June 22, 2015
06:32 EDTBAXKamada collaborates with Baxter on clinical trial with Alpha-1 antitrypsin
Kamada (KMDA) reports that the company has entered into a collaboration with Baxalta International, a wholly-owned subsidiary of Baxter (BAX) on a Phase 1/2 clinical trial of Kamada’s proprietary alpha-1 antitrypsin treatment for the prevention of lung transplant rejection. Under the agreement, Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel. The study is expected to initiate in the first half of 2016, with more details on trial design to be provided at a later date. Kamada’s proprietary, highly-purified, liquid form of human AAT has shown positive interim results in a proof-of-concept Phase II study in Graft-versus-Host-Disease conducted at the Fred Hutchinson Cancer Research Center in cooperation with Baxalta. Based on those results, preclinical data published in Blood, and at the American Society of Hematology meeting, and a similar mechanism of action, the companies now plan to expand the AAT indication to the prevention of lung transplant rejection and may use this data to support clinical development worldwide. Baxalta has distribution rights to intravenous AAT for all indications in the U.S., Canada, Australia and New Zealand, while Kamada has rights in all other territories and all other formulations.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use